Understanding how Cdkn2a can relay to initiate a thermogenic program in hiPSC-BAPs is a first step to envisage activating beiging as a new putative therapy to alleviate the effects of obesity and to prevent insulin resistance and T2D. The gene discussed is CDKN2A; the disease is obesity due to melanocortin 4 receptor deficiency.